KR20230044252A - 인플루엔자를 치료 또는 예방하기 위한 폴리시클릭 캡-의존성 엔도뉴클레아제 억제제 - Google Patents
인플루엔자를 치료 또는 예방하기 위한 폴리시클릭 캡-의존성 엔도뉴클레아제 억제제 Download PDFInfo
- Publication number
- KR20230044252A KR20230044252A KR1020237006229A KR20237006229A KR20230044252A KR 20230044252 A KR20230044252 A KR 20230044252A KR 1020237006229 A KR1020237006229 A KR 1020237006229A KR 20237006229 A KR20237006229 A KR 20237006229A KR 20230044252 A KR20230044252 A KR 20230044252A
- Authority
- KR
- South Korea
- Prior art keywords
- int
- mmol
- compound
- alkyl
- found
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063056861P | 2020-07-27 | 2020-07-27 | |
| US63/056,861 | 2020-07-27 | ||
| PCT/US2021/042711 WO2022026285A1 (en) | 2020-07-27 | 2021-07-22 | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230044252A true KR20230044252A (ko) | 2023-04-03 |
Family
ID=80038102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237006229A Pending KR20230044252A (ko) | 2020-07-27 | 2021-07-22 | 인플루엔자를 치료 또는 예방하기 위한 폴리시클릭 캡-의존성 엔도뉴클레아제 억제제 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240018145A1 (https=) |
| EP (1) | EP4188379B1 (https=) |
| JP (1) | JP7695339B2 (https=) |
| KR (1) | KR20230044252A (https=) |
| CN (1) | CN116490190A (https=) |
| AU (1) | AU2021315475A1 (https=) |
| BR (1) | BR112023001325A2 (https=) |
| CA (1) | CA3187516A1 (https=) |
| MX (1) | MX2023001194A (https=) |
| WO (1) | WO2022026285A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118804908A (zh) * | 2022-03-01 | 2024-10-18 | 弗门尼舍有限公司 | 制备γ,δ-不饱和醛衍生物的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) * | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| EA200801144A1 (ru) | 2005-10-27 | 2008-10-30 | Сионоги Энд Ко., Лтд. | Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич |
| MX2013003139A (es) | 2010-09-24 | 2013-06-18 | Shionogi & Co | Profarmaco de derivado de carbamoilpiridona policiclica substituida. |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| EP4257137A3 (en) * | 2018-05-31 | 2023-11-01 | Shionogi & Co., Ltd | Polycyclic carbamoylpyridone derivatives for the treatment of hiv |
| AU2019277547B2 (en) | 2018-05-31 | 2024-10-10 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative |
| CN113286793B (zh) | 2018-09-10 | 2024-04-05 | 共结晶制药公司 | 吡咯并吡嗪和吡啶并三嗪类流感病毒复制抑制剂 |
-
2021
- 2021-07-22 KR KR1020237006229A patent/KR20230044252A/ko active Pending
- 2021-07-22 EP EP21848925.0A patent/EP4188379B1/en active Active
- 2021-07-22 CA CA3187516A patent/CA3187516A1/en active Pending
- 2021-07-22 JP JP2023505421A patent/JP7695339B2/ja active Active
- 2021-07-22 CN CN202180065598.0A patent/CN116490190A/zh active Pending
- 2021-07-22 BR BR112023001325A patent/BR112023001325A2/pt unknown
- 2021-07-22 US US18/015,465 patent/US20240018145A1/en active Pending
- 2021-07-22 MX MX2023001194A patent/MX2023001194A/es unknown
- 2021-07-22 AU AU2021315475A patent/AU2021315475A1/en active Pending
- 2021-07-22 WO PCT/US2021/042711 patent/WO2022026285A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN116490190A (zh) | 2023-07-25 |
| EP4188379B1 (en) | 2026-02-25 |
| US20240018145A1 (en) | 2024-01-18 |
| JP7695339B2 (ja) | 2025-06-18 |
| EP4188379A4 (en) | 2024-08-28 |
| MX2023001194A (es) | 2023-04-20 |
| EP4188379A1 (en) | 2023-06-07 |
| CA3187516A1 (en) | 2022-02-03 |
| BR112023001325A2 (pt) | 2023-02-14 |
| AU2021315475A1 (en) | 2023-03-02 |
| WO2022026285A1 (en) | 2022-02-03 |
| AU2021315475A8 (en) | 2023-04-06 |
| JP2023535771A (ja) | 2023-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7060298B1 (ja) | Ｍｇａｔ２阻害活性を有する縮合環誘導体 | |
| US7968564B2 (en) | HIV integrase inhibitors | |
| JP2021500345A (ja) | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト | |
| US20070275990A1 (en) | Heterocyclic Spiro Compound | |
| KR20210019489A (ko) | B형 간염 캡시드 조립 조절제 | |
| WO2002038153A1 (en) | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives | |
| MX2015002807A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble. | |
| JP2019527233A (ja) | スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 | |
| EP3697781B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| JP2021513519A (ja) | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト | |
| CN113227093A (zh) | 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法 | |
| RS63203B1 (sr) | Jedinjenja korisna kao inhibitori ripk1 | |
| EA036965B1 (ru) | Ингибиторы деацетилаз гистонов и композиции и способы их применения | |
| AU2005214319B2 (en) | Amino heterocyclic modulators of chemokine receptor activity | |
| US20020198189A1 (en) | New use | |
| JP7695339B2 (ja) | インフルエンザを治療又は予防するための多環式キャップ依存性エンドヌクレアーゼ阻害薬 | |
| US20240199640A1 (en) | Negative allosteric modulators of metabotropic glutamate receptor 2 | |
| RU2841261C1 (ru) | Полициклические ингибиторы кэп-зависимой эндонуклеазы для лечения или профилактики гриппа | |
| JP2022542390A (ja) | ジヒドロピリミジン誘導体及びｈｂｖ感染又はｈｂｖ誘導性疾患の処置におけるその使用 | |
| WO2024151465A1 (en) | Protease inhibitors for treating or preventing coronavirus infection | |
| WO2023018913A1 (en) | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza | |
| JP2023519605A (ja) | 核内受容体に対して活性な化合物 | |
| HK40058222A (en) | A crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |